Eleni Moraites, MD
Dermatology · Champaign, ILNPI 1417022161
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,985 of the $4,521 with a category attached, or 88.1%. It is spread thinly across 25 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,243 and has fallen 56.0% since, to $546 in 2025.
Across 236 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$890
- Novartis$856
- Johnson & Johnson$718
- Amgen$399
- UCB, Inc.$273
- Dermavant Sciences, Inc.$209
- plus $1K from 19 others
Across 6 payments — averaging $2098.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$13K
What the payments were for
- Food & beverage$3,98588%
- Education$53612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $890 |
| Novartis | 51 | $856 |
| Johnson & Johnson | 21 | $718 |
| Amgen | 22 | $399 |
| UCB, Inc. | 12 | $273 |
| Dermavant Sciences, Inc. | 16 | $209 |
| Lilly USA, LLC | 10 | $194 |
| Sun Pharmaceutical Industries Inc. | 10 | $175 |
| Sanofi | 5 | $110 |
| LEO Pharma Inc. | 5 | $88 |
| E.r. Squibb & Sons, L.L.C. | 4 | $82 |
| Pfizer | 5 | $76 |
| Regeneron Healthcare Solutions, Inc. | 4 | $65 |
| Incyte Corporation | 3 | $59 |
| Organon | 6 | $48 |
| Aclaris Therapeutics, Inc. | 2 | $43 |
| Genentech USA, Inc. | 2 | $43 |
| Galderma Laboratories, L.p. | 2 | $36 |
| Merz Pharmaceuticals, LLC | 1 | $30 |
| Smith+Nephew | 1 | $29 |
| Botanix SB Inc | 1 | $25 |
| Bristol Myers Squibb | 1 | $22 |
| Organogenesis Inc. | 1 | $19 |
| Verrica Pharmaceuticals Inc. | 1 | $19 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $12 |
How this compares
$4,521 in reported general payments places this provider in the 65th percentile of 606 dermatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 60 | $246,187 |
| OtezlaApremilast | 25 | $129,171 |
| Enbrel SureclickEtanercept | 13 | $91,508 |
| Humira(Cf) PenAdalimumab | 11 | $75,677 |
| ErivedgeVismodegib | 13 | $59,252 |
| Ketoconazole | 233 | $4,664 |
| Naftifine Hcl | 13 | $4,224 |
| Clobetasol Propionate | 79 | $3,773 |
| Betamethasone Dipropionate | 64 | $3,235 |
| Tacrolimus | 30 | $3,009 |
| Metronidazole | 40 | $2,266 |
| Desonide | 24 | $1,626 |
| Doxycycline Monohydrate | 63 | $1,338 |
| Fluorouracil | 20 | $1,290 |
| Clindamycin Phosphate | 27 | $1,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $399 | $129,17125 claims |
| Genentech USA, Inc.Erivedge | $43 | $59,25213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 606 dermatology providers in Illinois.
Other dermatology in Champaign
- Craig NeitzelChampaign$321K
- Ahmad AminNaperville$4.1M
- Raj ChovatiyaChicago$3.6M
- George LewittNorthbrook$3M
- Peter LioChicago$2.4M
- Elizabeth KiracofeChicago$1.6M
- Lana SchmidtEffingham$1.3M
- Melissa AbramsVernon Hills$600K
- Carolyn JacobChicago$566K
- Walter LiszewskiChicago$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.